[关键词]
[摘要]
玻璃体腔注射可在眼后节获得较高药物浓度,但药物仍受玻璃体扩散、内界膜穿透、组织清除和细胞摄取等因素影响,频繁注射也增加治疗负担。本文围绕玻璃体-内界膜-神经视网膜连续屏障,综述纳米载体、水凝胶与微球、植入物、微针和脉络膜上腔给药,以及病毒载体和细胞外囊泡的研究进展,并比较各平台的适用货物、作用部位、长效潜力与主要风险。现有临床证据主要来自植入式储库及部分脉络膜上腔制剂,纳米载体、水凝胶和囊泡系统多处于临床前阶段。后续研究应区分载体滞留与活性药物暴露,统一眼内分布、药代、功能和长期安全评价,并依据疾病部位及治疗目标选择给药平台。
[Key word]
[Abstract]
Intravitreal injection achieves high drug concentrations in the posterior segment, but drug exposure remains constrained by diffusion through the vitreous, penetration of the inner limiting membrane, tissue clearance, cellular uptake, and intracellular release. Frequent injections also increase treatment burden and procedure-related risk. This review discusses drug delivery across the vitreous-inner limiting membrane-neural retina continuum and examines nanoparticles, hydrogels and microspheres, intraocular implants, microneedle-assisted and suprachoroidal delivery, viral vectors, and extracellular vesicles. The platforms are compared according to therapeutic cargo, intended tissue compartment, duration of active drug exposure, and safety considerations. Clinical evidence is most developed for implantable reservoirs and selected suprachoroidal formulations, whereas most nanoparticle, hydrogel, and vesicle-based systems remain at the preclinical stage. A material that persists in the eye does not necessarily maintain an active drug concentration, and increased tissue fluorescence does not by itself demonstrate cell-specific delivery. Future studies should therefore distinguish carrier retention from pharmacologically active exposure, standardize measurements of ocular distribution, pharmacokinetics, function, and long-term safety, and select delivery platforms according to disease location and therapeutic goals.
[中图分类号]
[基金项目]
无